Sana’s UP421 Therapy Shows 14-Month Insulin Independence Without Immunosuppression
SANA•Sana Biotechnology’s UP421 hypoimmune-modified pancreatic islet cell therapy achieved insulin independence at 14 months without immunosuppressive drugs, marking sustained cell survival and function in a Type 1 diabetes patient. Twelve-week results were published in the New England Journal of Medicine, underscoring clinical validation ahead of potential pivotal trials.
1. UP421 14-Month Efficacy Data
In its first-quarter 2026 update, Sana reported that its UP421 hypoimmune-modified pancreatic islet cells achieved sustained insulin independence at 14 months in a Type 1 diabetes patient without any immunosuppression. This milestone demonstrates durable cell survival and function, a key hurdle for cell-based diabetes therapies.
2. Clinical Validation and Next Steps
Earlier 12-week results were published in the New England Journal of Medicine, providing peer-reviewed validation of UP421’s safety and efficacy. Sana plans to leverage these data to advance toward larger pivotal studies, potentially positioning UP421 as a leader in immunosuppression-free cell therapy for diabetes.
